文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Bile acids for metabolic dysfunction-associated steatotic liver disease in adults.

作者信息

Ashmawy Rehab E, Blyuss Oleg, Nikolova Dimitrinka, Pavlov Chavdar S, Gluud Christian, Andrenacci Paola J

机构信息

Faculty of Medicine, Helwan University, Cairo, Egypt.

Wolfson Institute of Population Health, Queen Mary University of London, London, UK.

出版信息

Cochrane Database Syst Rev. 2025 Sep 2;9(9):CD014850. doi: 10.1002/14651858.CD014850.

DOI:10.1002/14651858.CD014850
PMID:40891522
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12403225/
Abstract

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of oral bile acid-based therapies versus no intervention or placebo, or versus a different bile acid-based therapy, at any dose or regimen, in adults diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD).

摘要

相似文献

[1]
Bile acids for metabolic dysfunction-associated steatotic liver disease in adults.

Cochrane Database Syst Rev. 2025-9-2

[2]
Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis.

Cochrane Database Syst Rev. 2007-1-24

[3]
Silymarin for adults with metabolic dysfunction-associated steatotic liver disease.

Cochrane Database Syst Rev. 2025-6-24

[4]
Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis.

Cochrane Database Syst Rev. 2017-3-28

[5]
Alterations in Circulating Bile Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis.

Biomolecules. 2023-9-6

[6]
Vitamin E for people with non-alcoholic fatty liver disease.

Cochrane Database Syst Rev. 2024-10-16

[7]
Ursodeoxycholic acid for primary biliary cirrhosis.

Cochrane Database Syst Rev. 2012-12-12

[8]
Bile acids for liver-transplanted patients.

Cochrane Database Syst Rev. 2010-3-17

[9]
Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis.

Cochrane Database Syst Rev. 2017-3-30

[10]
Bile acids for viral hepatitis.

Cochrane Database Syst Rev. 2007-10-17

本文引用的文献

[1]
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).

J Hepatol. 2024-9

[2]
Effects of primary or secondary prevention with vitamin A supplementation on clinically important outcomes: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis.

BMJ Open. 2024-5-30

[3]
Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.

Hepatology. 2024-5-1

[4]
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review.

J Obes Metab Syndr. 2023-9-30

[5]
Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis.

Cell Metab. 2023-10-3

[6]
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.

J Hepatol. 2023-12

[7]
Changing epidemiology, global trends and implications for outcomes of NAFLD.

J Hepatol. 2023-9

[8]
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.

Hepatology. 2023-5-1

[9]
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.

Hepatology. 2023-4-1

[10]
Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention.

Cardiovasc Diabetol. 2022-12-3

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索